Brigatinib in crizotinib-refractory ALK+ non-small cell lung cancer (NSCLC): efficacy updates and exploratory analysis of target lesion response by baseline brain lesion status in the ALTA Trial. (January 2019) - Kim, D.; Huber, R.; Ahn, M.; Langer, C.; Tiseo, M.; West, H.; Groen, H.; Reckamp, K.; Hochmair, M.; Leighl, N.; Hansen, K.H.; Gettinger, S.; et al.